Asimadoline not checked
Tioga Pharmaceuticals · TP0052
FollowEvery change as it happens, and a Monday email
Trials
1 active
1 in total
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Asimadoline TP0052 2.5 mg two (2) tablets bid (two on awakening and two before bed), total of four (4) tablets daily (10 mg) for 8 weeks.”In the company’s words, NCT07042516 on ClinicalTrials.gov
- Tested for
- Vasomotor Symptoms
- Main trialPhase 2
- “This Phase 2a randomized, double-blind, placebo-controlled study evaluates the safety and efficacy of asimadoline (TP0052), a peripherally restricted selective kappa-opioid receptor agonist, for moderate to severe menopausal vasomotor symptoms (VMS) in women aged 40-62 years. Following screening and baseline VMS diary collection, eligible participants are randomized 1:1 to oral asimadoline 5 mg twice daily or matching placebo for 8 weeks. Following the double-blind treatment period, all participants receive 4 weeks of open-label asimadoline, with a safety telephone assessment at approximately…”In the company’s words, NCT07042516 on ClinicalTrials.gov
- Other names
- TP0052
Other drugs for Vasomotor Symptoms
- FezolinetantAstellas · Phase 3
- ElinzanetantBayer · Phase 3
Coming up1
- 31 Oct 2027Phase 2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Recruiting | 31 Oct 2027 | Safety and Efficacy of Asimadoline (TP0052) in Patients With Vasomotor Symptoms (VMS). |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026